Key result
Medical therapy for pulmonary arterial hypertension includes epoprostenol, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors, with combination therapy becoming increasingly common.
A review of current and emerging medical therapies for pulmonary arterial hypertension, highlighting the increasing use of combination therapy despite a lack of guideline consensus.
Combination therapy is increasingly used in PAH despite lacking consensus; leaves open need for RCTs to define optimal regimens.
Recent advances in the understanding of pulmonary arterial hypertension have led to new therapeutic options, although the disease remains incurable and continues to cause substantial morbidity and mortality. Disease-specific therapies have been approved for use in the US, including epoprostenol and its various analogs, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors. The use of combination therapy with agents from more than one of these drug classes is becoming increasingly common, although guidelines establishing optimal combinations are lacking. Meanwhile, potential future therapeutic options are actively being pursued.
No takes yet. Share an insight, caveat, or question.
Driscoll et al. (2007) conducted a review in Pulmonary arterial hypertension. Medical therapy (epoprostenol, endothelin receptor antagonists, phosphodiesterase 5 inhibitors) was evaluated. Medical therapy for pulmonary arterial hypertension includes epoprostenol, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors, with combination therapy becoming increasingly common.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: